Trader consensus heavily favors no hantavirus vaccine approval or availability in 2026, driven by the absence of any candidate in late-stage clinical trials as of mid-2026. Inactivated vaccines exist for select Old World strains in China and South Korea, yet no product protects against New World hantaviruses like Andes virus, and none is licensed by the FDA or EMA. Recent 2026 outbreaks have accelerated preclinical work on DNA and mRNA platforms, including promising early immunogenicity data, but timelines for Phase 1–3 testing and regulatory review typically span multiple years without extraordinary funding acceleration. Market-implied odds reflect this realistic barrier while allowing for rare breakthroughs if trials launch imminently with strong results.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% 概率
$129,623 交易量
$129,623 交易量
2026-12-31
6% 概率
$129,623 交易量
$129,623 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus heavily favors no hantavirus vaccine approval or availability in 2026, driven by the absence of any candidate in late-stage clinical trials as of mid-2026. Inactivated vaccines exist for select Old World strains in China and South Korea, yet no product protects against New World hantaviruses like Andes virus, and none is licensed by the FDA or EMA. Recent 2026 outbreaks have accelerated preclinical work on DNA and mRNA platforms, including promising early immunogenicity data, but timelines for Phase 1–3 testing and regulatory review typically span multiple years without extraordinary funding acceleration. Market-implied odds reflect this realistic barrier while allowing for rare breakthroughs if trials launch imminently with strong results.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市场开放时间： May 4, 2026, 10:39 AM ET
交易量
$129,623结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus heavily favors no hantavirus vaccine approval or availability in 2026, driven by the absence of any candidate in late-stage clinical trials as of mid-2026. Inactivated vaccines exist for select Old World strains in China and South Korea, yet no product protects against New World hantaviruses like Andes virus, and none is licensed by the FDA or EMA. Recent 2026 outbreaks have accelerated preclinical work on DNA and mRNA platforms, including promising early immunogenicity data, but timelines for Phase 1–3 testing and regulatory review typically span multiple years without extraordinary funding acceleration. Market-implied odds reflect this realistic barrier while allowing for rare breakthroughs if trials launch imminently with strong results.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$129,623结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus heavily favors no hantavirus vaccine approval or availability in 2026, driven by the absence of any candidate in late-stage clinical trials as of mid-2026. Inactivated vaccines exist for select Old World strains in China and South Korea, yet no product protects against New World hantaviruses like Andes virus, and none is licensed by the FDA or EMA. Recent 2026 outbreaks have accelerated preclinical work on DNA and mRNA platforms, including promising early immunogenicity data, but timelines for Phase 1–3 testing and regulatory review typically span multiple years without extraordinary funding acceleration. Market-implied odds reflect this realistic barrier while allowing for rare breakthroughs if trials launch imminently with strong results.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题